Lactulose Fresenius (Lactulose, Liquid)

Lactulose is a synthetic sugar that reaches the colon unchanged, where intestinal bacteria ferment it into short‑chain fatty acids. This fermentation creates an osmotic gradient that pulls water into the bowel, softening stool. The resulting acidic environment also converts ammonia to non‑absorbable ammonium, lowering blood ammonia levels.

The dose of Lactulose Fresenius is individualized by the prescribing clinician based on the patient’s condition, severity, and response. The prescriber determines the appropriate volume and frequency, which may be adjusted during treatment to achieve the desired therapeutic effect.

Safety data for Lactulose Fresenius in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision should be made by a qualified healthcare professional after evaluating the clinical situation.

To order Lactulose Fresenius, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lactulose is an osmotic laxative, differing from stimulant laxatives that increase intestinal motility. Compared with polyethylene glycol solutions, lactulose also reduces ammonia absorption, making it the preferred choice for patients with hepatic encephalopathy, whereas other laxatives lack this additional benefit.

Lactulose Fresenius should be stored at ambient temperature, below 25 °C, in its original container. Protect the product from moisture, direct sunlight and extreme temperatures to maintain stability and potency throughout its shelf life.

Lactulose Fresenius is taken orally as a liquid. The prescribed volume is measured using a calibrated device and consumed directly or mixed with a small amount of water or juice, as directed by the healthcare provider.

Serious risks include severe electrolyte disturbances such as hyponatremia or hypokalemia, marked dehydration from excessive diarrhea, and rare allergic reactions. Patients should be monitored for signs of these conditions, especially during high‑dose or prolonged therapy.

Lactulose Fresenius is contraindicated in patients with known hypersensitivity to lactulose or any component of the formulation. Caution is advised in individuals with intestinal obstruction, severe dehydration, or those requiring strict fluid restriction, as the product may exacerbate these conditions.